CytoDyn closes $16.5 million financing to fund leronlimab development
CytoDyn says it has closed a $16.5 million financing to fund continued development of leronlimab, its humanized monoclonal antibody targeting the CCR5 receptor.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.